[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613032":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":26,"studyPopulation":18,"armGroups":27,"interventions":39,"overallOfficials":48,"centralContacts":53,"locations":59,"responsibleParty":78,"collaborators":18,"id":80,"slug":18,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":18,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":62,"whyStopped":18,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Lahore General Hospital","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Efficacy Achievement","The primary outcome will be the proportion of participants who demonstrate a minimum 75 percent reduction in the Severity Index (PASI-75) from baseline to Week 12 of treatment. A participant will be classified as \"Achieved\" if the Week-12 PASI score reflects a reduction of 75 percent or greater from the baseline measurement, and \"Not Achieved\" if this threshold is not met.","Baseline to Week 12 of treatment",[14],{"measure":15,"description":16,"timeFrame":17},"Percentage Reduction in PASI Score","This outcome will quantify the degree of improvement by calculating the percentage reduction in PASI score from baseline to Week 12. Percentage reduction will be computed using the formula:\n\n\\[(Baseline PASI - Week-12 PASI) ÷ Baseline PASI\\] × 100.","From Baseline to Week 12",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":22,"primaryPurpose":23,"observationalModel":18,"timePerspective":18,"maskingInfo":24},"RANDOMIZED","PARALLEL","Randomized control trial","TREATMENT",{"masking":25,"maskingDescription":18,"whoMasked":18},"NONE","Comparison between safety and efficacy of oral methotrexate and tofacitinib in chronic plaque psoriasis is to be determined in this study",[28,34],{"label":29,"type":30,"description":31,"interventionNames":32},"Group mTX","ACTIVE_COMPARATOR","Methotrexate is a modified antirheumatic drug work by inhibiting dihydrofolate reductase",[33],"Drug: Methotrexate",{"label":35,"type":30,"description":36,"interventionNames":37},"Tofacitinib","Tofacitinib is janus kinase inhibitor and had a role in treatment of psoriasis and psoriatic arthritis",[38],"Drug: Tofacitinib",[40,45],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":18},"DRUG","Methotrexate","Methotrexate is an antifolate drug work by inhibiting enzyme dihydrofolate reductase and inhibit cell proliferation and play a role in psoriasis treatment",[29],{"type":41,"name":35,"description":46,"armGroupLabels":47,"otherNames":18},"Tofacitinib is janus kinase inhibitor and have role in psoriasis",[35],[49],{"name":50,"affiliation":51,"role":52},"Maryam Fatima","Lahore General Hospital, Lahore","PRINCIPAL_INVESTIGATOR",[54],{"name":55,"role":56,"phone":57,"phoneExt":18,"email":58},"Maryam Fatima, Mbbs","CONTACT","03361409014","maryamfatima726@yahoo.com",[60],{"facility":61,"status":62,"city":63,"state":64,"zip":18,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"Lahore general hospital","RECRUITING","Lahore","Punjab Province","Pakistan","PK",{"type":68,"coordinates":69},"Point",[70,71],74.35071,31.558,{"lat":71,"lon":70},[74],{"name":75,"role":56,"phone":76,"phoneExt":18,"email":77},"Dr Ayesha Wahid, Fcps","+92 323 4822177","zaeemakanwal@hotmail.com",{"type":52,"investigatorFullName":50,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Principal Investigator","100613032",false,"NCT07261306","Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis","MTX","Inclusion Criteria:\n\n* Patients aged 18- 70 years of either gender.\n* Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and\u002For Body Surface Area (BSA) involvement of 10% or more, will be included.\n* Duration of plaque psoriasis for at least 6 months prior to the study.\n* Psoriasis that has not shown adequate response to topical therapies\n\nExclusion Criteria:\n\n* Individuals with other forms of psoriasis or other significant dermatological conditions that might interfere with the assessment of psoriasis.\n* Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded.\n* Known hypersensitivity or contraindications to either methotrexate or tofacitinib.\n* History of significant liver, kidney, hematologic\u002Fbleeding disorder, gastrointestinal\u002Facid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy.\n* Pregnant or lactating women will not be eligible for the study.",true,"ALL","18 Years","70 Years",{"count":91,"type":92},75,"ESTIMATED","INTERVENTIONAL",[95],"EARLY_PHASE1","Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study",[98],"Psoriasis",[100,35],"MtX","2025-11-21",{"date":103,"type":104},"2025-12-03","ACTUAL",{"date":106,"type":104},"2025-08-29",{"date":108,"type":92},"2025-12-25",{"name":5,"class":6},1]